Advanced search
Publication Cover
Expert Review of Vaccines Volume 3, 2004 - Issue 1
Submit an article Journal homepage
165
Views
42
CrossRef citations to date
0
Altmetric
Review

Serologic correlates of protection for evaluating the response to meningococcal vaccines

Paul Balmer Vaccine Evaluation Department, NW Regional HPA Laboratory, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, UK. [email protected]
&
Ray Borrow Vaccine Evaluation Department, NW Regional HPA Laboratory, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, UK. [email protected]
Pages 77-87 | Published online: 09 Jan 2014

References

  • World Health Organization. Weekly Epidemiological Record37, 281–288 (2001).
  • Fairley CK, Begg N, Borrow R et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants.' Infect. Dis. 174, 1360–1363 (1996).
  • Richmond P, Borrow R, Miller E et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory." Infect. Dis. 179, 1569–1572 (1999).
  • Richmond P, Borrow R, Findlow J et al. Evaluation of de-O-acetylated meningococcal C polysaccharide—tetanus toxoid conjugate vaccine in infancy: Reactogenicity, immunogenicity, immunologic priming and bactericidal activity against 0-acetylated and de-0-acetylated serogroup C strains. Infect. Immun. 69, 2378–2382 (2001).
  • Richmond P, Borrow, R, Goldblatt D et al. Ability of three different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 183,160–163 (2001).
  • Bramley JC, Hall T, Finn A et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2,3 and 4 months of age. Vaccine 19,2924–2931 (2001).
  • Rennels MB, Edwards KM, Keyserling HE et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr. Infect. Dis. J. 20, 153–159 (2001).
  • W'le FA, Artenstein MS, Brandt BL et al. Immunological response of man to group B meningococcal polysaccharide antigens." Infect. Dis. 126,514–522 (1972).
  • Finne J, Leinonen M, Makeld PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2, 355–357 (1983).
  • Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338,1093–1096 (1991).
  • Sierra GVG, Campa HC, Varcacel NW et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. Nad Inst. Public Health Ann. 14,195–207 (1991).
  • Cassio de Moraes J, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo,Brazil. Lancet 340,1074–1078 (1992).
  • Boslego J, Garcia J, Cruz C et at Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13, 821–829 (1995).
  • Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA187O.j Exp. Med 197, 789–799 (2003).
  • Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis.j Exp. Med. 195, 1445–1454 (2002).
  • Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatn Infect. Dis. J. 3,187–195 (2000).
  • Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20, S58—S67 (2001).\Summarizes the UK immunization campaign against serogroup C disease.
  • Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceutical Officer. Extending meningitis C vaccine to 20–24 year olds; Pneumomccil vaccine for at-risk under 2 year olds. PL/CMO/2002/1, PUCNO/2002/1, PUCPH0/2002/1 (2002).
  • Balmer R Borrow Miller, R. E. Impact of meningococcal C conjugate vaccine in the UK. J. Med Microbid 51,717–722(2002).
  • Ramsay ME, Andrews NJ, Trotter CL, Kac2marski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br. Med. 326,365-366 (2003).
  • Maiden M, Stuart J and The United Kingdom Meningomcril Carriage Group. Reduced caniage of serogroup C meningococci in teenagers one year after the introduction of meningomcril C conjugate polysaccharide vaccine in the United Kingdom. Lancet 359,1829–1851 (2002).
  • •Clearly shows the reduction of serogroup C carriage following immunization with conjugate vaccine.
  • Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies.' Exp. Med. 129,1307-1326 (1969).
  • ••Pioneering studies that set the originalcorrelate of protection for serogroup C.
  • Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: II. Development of natural immunity.' E. Med. 129,1327-1348 (1969).
  • ••Pioneering studies that set the originalcorrelate of protection for serogroup C.
  • World Health Organisation. Requirements for meningococcal polysaccharide vaccine. World Health Organization technical report series, no. 594. World Health Organization, Geneva, Switzerland (1976).
  • Griffis JM, Goroff DK. IgA blocks Ig/VI and IgG-initiated immune lysis by separate molecular mechanisms.' Immunol. 130, 2882–2885 (1983).
  • Zollinger WD, Mandrell RE Importance of complement source in bactericidal activity of human antibody and rnurine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40, 257–264 (1983).
  • Trotter C, Borrow R, Andrews N, Miller E Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the prevaccination era. Vaccine 21, 1094–1098 (2003).
  • Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: re-evaluation of correlates of protection. Infect. Immun. 69,1568–1573 (2001).
  • •Reevaluated the correlates of protection for serogroup C.
  • Farrington P Miller E Meningococcal vaccine trials. In: Methods in Molecular Medicine: Meningococcal Vaccines. AJ Pollard, MCJ Maiden (Eds.), Humana press, NJ, USA, 371–393 (2001).
  • Andrews, N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from postlicensure surveillance in England. Clin. Diag. Lab. Immunol. 10,780–786 (2003).
  • •Validates the serological correlate of protection for serogroup C.
  • Borrow R, Goldblatt D, Andrews Net al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom.' Infect Dis. 186, 1353–1357 (2002).
  • Goldblatt D, Pinto Vaz, ARJPM, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae Type b conjugate vaccines following infant immunization.' Infect. Dis. 177, 1112–1115 (1998).
  • Joseph H, Miller E, Dawson M et al. Meningococcal serogroup A avidity indices as a surrogate marker of priming for the induction of immunological memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom.' Infect. Dis. 184,661–662 (2001).
  • Goldblatt D, Borrow R, Miller E. Natural and vaccine-induced immunity and immunologic memory to 1Veisseria meningitidis serogroup C in young adults.' Infect. Dis. 185,397-400 (2002).
  • Konradsen HB. Quality and avidity of pneumococcal antibodies before and five years after pneumococcal vaccination of elderly persons. Clin. Infect. as. 21, 616–620 (1995).
  • Wuorimaa T, Käyhty H, Leroy 0, Eskola J. Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine 19,1863–1869 (2001).
  • Rosenqvist E, Hoiby EA. Relative bactericidal activity of IgG antibodies against outer membrane complex from meningococci, as a function of vaccine type, dose and time after vaccination. In: 1Veisseriae —1990. Achtman M, Kohl P, Marchal C et aZ (Eds.), Walter de Gruyter, Berlin, Germany and NY, USA, 265–269 (1990).
  • Peltola H, Mäkelä H, Käyhty H et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl. Med 297,686–691 (1977).
  • •Provides the first insight into correlates of protection for serogroup A.
  • Mäkeld PH, Käyhty H, Weckström P, Sivonen E, Renkonen 0-V. Effect of group A meningococcal vaccine in army recruits in Finland. Lancet 2,883–886 (1975).
  • MacLennan J, Obaro S, Deeks J et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 17,3086–3093 (1999).
  • Leach A, Twumasi PA, Kumah S et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide—protein conjugate vaccine.' Infect. Dis. 175, 200–204 (1997).
  • Borrow R, Joseph H, Andrews N et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 19,1129–1132 (2000).
  • Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.' Clin. Invest. 56,1536-1547 (1975)•.
  • Joseph H, Ryall R, Bybel M et al.Immunogenicity and immunological priming of the serogroup A portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children.' Infect. Dis. 187,1142-1146 (2003).
  • Jokhdar H, Borrow R, Sultan A et al. Immunologic hyporesposiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin. Diagn. Lab. Immuna 11, 83–88 (2004).
  • Milagres LG, Ramos SR, Sacchi cr et al. Immune response of Brazilian children to a 1Veisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62,4419 '1/124(1994).
  • Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of two serogroup B outer- membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JANIA 28, 1520–1527 (1999).
  • Ho1st J, Feiring B, Fuglesang JE et al Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21, 734–737 (2003).
  • •Evaluates data from an outer membrane vesicle vaccine trial to further understand correlates of protection for serogroup B.
  • Martin D, Glennie A, McCallum L et al. Validating the serum bactericidal assay for group B meningococci for use in clinical trials. Seventh meeting of the European Monitoring Group for Meningococci. Lanzarote, Spain. P55 (2003).
  • Longworth E, Borrow R, Goldblatt D et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 20, 2592–2596 (2002).
  • Vermont CL, van Dijken HH, van Limpt q et al. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent merungo. coccal B outer membrane vesicle vaccine. Infict. Immun. 70, 584–590 (2002).
  • Ison CA, Heyderman RS, Klein NJ, Peakman M, Levin M. Whole blood model for exploring host—bacterial interactions. Microb. Pathog. 18, 97–107 (1995).
  • Ison CA, Anwar N, Cole MJ et al. Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microb. Pathog. 27, 207–214 (1999).
  • Ison CA, Anwar N, Cole MJ et al. Age dependence of in vitro survival of meningococci in whole blood during childhood. Pediatr. Infect. Dis. J. 22, 868–873 (2003).
  • Bredius RG, Derkx BH, Fijen CA et al Fcy receptor Ha (CD32) polymorphism in fidrninent meningococcal shock in children." Infect. Dis. 170, 848–853 (1994).
  • Estabrook MM, Christopher NC, Griffiss JM, Baker q, Mandrell RE. Sialylation and human neutrophil killing of group C 1Veisseria meningitidis.j Infect. Dis. 166, 1079–1088 (1994).
  • Schlesinger M, Greenberg R, Levy J, Käythy H, Levy R Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency J Infect. Dis. 170, 449–453 (1994).
  • Fredlund A, Olcen P, Danielsson D. A reference procedure to study chemiluminesence induced in. polymorphonuclear leukocytes by Neisseria meningitidis. Acta Pathol Microbial Immunol Scand. Sect. 96, 941–949 (1988).
  • Gomez-Lus ML, Aguilar L, Vazquez J et al. Ex vivo bactericidal activity against group C Neisseria meningitidis in seronegative subjects. Infection 28, 305–308 (2000).
  • Halstensen A, Sjursen H, Vollset SE et al. Serum opsonins to serogroup B meningococci in meningococcal disease." Infect. Dis. 21, 267–276 (1989).
  • Lowell GH, Smith LF, Artenstein MS, Nash GS, MacDermott Jr RP. Antibody dependent cell mediated antibacterial activity of human mononuclear cells. I. K lymphocytes and monocytes are effective against meningococci in cooperation with human immune sera." E. Med. 150, 127–137 (1979).
  • Smith LF, Lowell GH. Antibody-dependent cell mediated antibacterial activity of human mononuclear cells. II. Immune specificity of antimeningococcal activity. J Infect. Dis. 141, 748–751 (1980).
  • Martinez JE, Romero-Steiner S, Pilishvili T et al. A flow cytometric opsonophagocytic assay for the measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. Chn. Diagn. Lab. Immun. 6, 581–586 (1999).
  • Martinez J, Pilishvili T, Barnard S et id Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y or W-135 polysaccharide correlates with serum bactericidal activity. Chn. Diagn. Lab. Immunol 9, 485–488 (2002).
  • Aase A, Hoiby EA, Michaelsen TE Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. j Immunol 47, 388–396 (1998).
  • Michaelsen TE, Aase A, Kolberg J, Wedge E, Rosenqvist E. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria. Vaccine 19, 1526–1533 (2001).
  • Aase A, Naess LM, Sandin RH et al. Comparison of functional immune responses in humans after intranasal and intramuscular immunizations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 21, 2042–2051 (2003).
  • Gomez-Lus ML, Gimenez MJ, Vazquez JA et al. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination. Infection 31, 51–54 (2003).
  • Funnell SGP, Taylor S, Pryer H et al. Developing of meningococcal whole cell antibody surface labeling and opsonophagocytic assays for assessment of vaccines containing proteins. 13th International Pathogenic Neisseria Conference, Oslo, Norway. P251(2002).
  • Holbein BE. Iron-controlled infection with Neisseria meningitidis in mice. Infect. Immun. 29, 886–891 (1980).
  • Huet M, Suire A. An animal model for testing the activity of meningococcal polysaccharide vaccine." Bial Stand 9, 67–74 (1981).
  • Martin D, Cadieux N, Hamel J, Brodeur BR Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.' Exp. Med 185, 1173–1183 (1997).
  • Brodeur BR, Larose Y, Tsang P, Hamel J, Ryan A. Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody. Infect. Immun. 50, 510–516 (1985).
  • Oliver KJ, Reddin KM, Bracegirdle P et al. Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun. 70, 3621–3626 (2002).
  • Saukkonen K, Leinonen M, Abdillahi H, Poolman JT. Comparitive evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7, 325–328 (1989).
  • Toropainen M, Käyhty H, Saarinen Let al. The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine 7, 2677–2689 (1999).
  • Toropainen M, Saarinen L, van der Ley P, Kuipers B, Käyhty H. Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model. Microb. Pathol 30, 139–148 (2001).
  • Schmidt S, Zhu D, Bamiak Vet al. Passive immunization with Neisseria meningitidis PorA specific immune sera reduces nasopharyngeal colonization of group B meningococcus in an infant rat nasal challenge model. Vaccine 19, 4851–4858 (2001).
  • Toropainen M, Saarinen L, Käyhty H, Makelä PH. The Icelandic Study Group. Passive protection in the infant rat protection assay (IRPA) by sera taken after vaccination of young adults by two serogroup B meningococcal outer membrane vesicle vaccines in Iceland. 13th International Pathogenic Neisseria Conference, Oslo, P302 (2002). soToropainen M, Saarinen L, Bolstad K et al. Are IgiVI antibodies to meningococcal serogroup B capsular polysaccharide responsible for passive protection by prevaccination sera in the infant it protection assay (IRPA)? 13th International Pathogenic Neisseria Conference„ Oslo, P303 (2002).
  • Plested JS, Harris SL, Wright JC et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia.j Infect. Dis. 187,1223–1234 (2003).
  • Harris SL, Finn A, Granoff DM. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis—diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect. Immun. 71,3402–3408 (2003).
  • Welsch JA, Moe GR, Rossi R et al. Antibody to genome-derived Neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. 188,1730-1740 19 (2003).
  • Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method.' Infect. Dis. 188, 481–485 (2003).
  • Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceutical Officer. Planned Hib Vaccination Catch-up Campaign. PL/CMO/2003/1, PUCNO/2003/ 1, PL/ CPHO/2003/ 1 (2003).
  • Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceutical Officer. Planned Hib Vaccination Catch-up Campaign — further information. PUCM0/2003/2, PL/CNO/2003/2, PUCPH0/2003/2 (2003).
  • Goldblatt D, Richmond P, Millard E, Thornton C, Miller E. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus and pertussis vaccine combination.' Infect. Dis. 180,538–541 (1999).
  • Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361,1902–1904 (2003).
  • Baker MG, Martin DR, Kieft CEM, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: Descriptive epidemiology, 1991–2000." Paediatr. Child Health 37, S13—S19 (2001).
  • Hoist J, Aaberge IS, Oster P et al A 'tailor made' vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Eurosurveillance Weekly 7,030724 (2003).

Websites

  • Surveillance of impact of meningococcal serogroup C conjugate vaccination program in England, and Wales and protocol for investigation of vaccine failures:Joint document from the Health Protection Agency and the Institute of Child Health, London www.hpa.org.uk/infectionshopics_az/advic e/mensurvw99.pdf.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.